

The BiomolBiomed publishes an “Advanced Online” manuscript format as a free service to authors in order to expedite the dissemination of scientific findings to the research community as soon as possible after acceptance following peer review and corresponding modification (where appropriate). **An “Advanced Online” manuscript is published online prior to copyediting, formatting for publication and author proofreading, but is nonetheless fully citable through its Digital Object Identifier (doi®). Nevertheless, this “Advanced Online” version is NOT the final version of the manuscript.** When the final version of this paper is published within a definitive issue of the journal with copyediting, full pagination, etc., the final version will be accessible through the same doi and this “Advanced Online” version of the paper will disappear.

## SUPPLEMENTAL DATA

# **Construction of the prognostic nomogram and treatment recommendation in patients with mixed endometrial carcinoma treated with hysterectomy**

**Table S1.** Baseline demographic and clinical characteristics with mixed endometrial carcinoma patients of the training and test sets in our study

Characteristics	Total	The training set	The test set	<i>P</i>
	No. (%)	No. (%)	No. (%)	
Age at diagnosis (y)				0.947
≤63	3833 (52.8%)	2682 (52.8%)	1151 (52.9%)	
64~77	2687 (37.0%)	1878 (37.0%)	809 (37.2%)	
≥78	736 (10.1%)	519 (10.2%)	217 (9.97%)	
Race				0.730
White	5802 (80.0%)	4082 (80.4%)	1720 (79.0%)	
Black	753 (10.4%)	513 (10.1%)	240 (11.0%)	
Asian/Pacific Islander	623 (8.59%)	430 (8.47%)	193 (8.87%)	
American Indian/ Alaska Native	40 (0.55%)	27 (0.53%)	13 (0.60%)	
Unknown	38 (0.52%)	27 (0.53%)	11 (0.51%)	
Marital status				0.642
Married	3575 (49.3%)	2484 (48.9%)	1091 (50.1%)	
Unmarried	1468 (20.2%)	1044 (20.6%)	424 (19.5%)	
Divorced/Separated	883 (12.2%)	625 (12.3%)	258 (11.9%)	
Widowed	1046 (14.4%)	722 (14.2%)	324 (14.9%)	
Unknown	284 (3.91%)	204 (4.02%)	80 (3.67%)	
Tumor size (mm)				0.558
1~38	1572 (21.7%)	1087 (21.4%)	485 (22.3%)	

39~59	872 (12.0%)	618 (12.2%)	254 (11.7%)	
≥60	797 (11.0%)	546 (10.8%)	251 (11.5%)	
Unknown	4015 (55.3%)	2828 (55.7%)	1187 (54.5%)	
Grade				0.515
Grade I	1206 (16.6%)	823 (16.2%)	383 (17.6%)	
Grade II	1274 (17.6%)	903 (17.8%)	371 (17.0%)	
Grade III	1774 (24.4%)	1260 (24.8%)	514 (23.6%)	
Grade IV	798 (11.0%)	555 (10.9%)	243 (11.2%)	
Unknown	2204 (30.4%)	1538 (30.3%)	666 (30.6%)	
SEER-Stage*				0.988
Localized	4391 (60.5%)	3075 (60.5%)	1316 (60.5%)	
Regional	2217 (30.6%)	1550 (30.5%)	667 (30.6%)	
Distant	667 (30.6%)	429 (8.45%)	182 (8.36%)	
Unknown	37 (0.51%)	25 (0.49%)	12 (0.55%)	
AJCC-Stage				0.961
I	2820 (38.9%)	1973 (38.8%)	847 (38.9%)	
II	339 (4.67%)	234 (4.61%)	105 (4.82%)	
III	961 (13.2%)	670 (13.2%)	291 (13.4%)	
IV	376 (5.18%)	269 (5.30%)	107 (4.92%)	
Unknown	2760 (38.0%)	1933 (38.1%)	827 (38.0%)	
AJCC-T				0.937
T1	3145 (43.3%)	2194 (43.2%)	951 (43.7%)	

T2	480 (6.62%)	334 (6.58%)	146 (6.71%)	
T3	795 (11.0%)	561 (11.0%)	234 (10.7%)	
T4	98 (1.35%)	72 (1.42%)	26 (1.19%)	
Unknown	2738 (37.7%)	1918 (37.8%)	820 (37.7%)	
NPR-Lymph node				0.830
0	4248 (58.5%)	2963 (58.3%)	1285 (59.0%)	
1	358 (4.93%)	243 (4.78%)	115 (5.28%)	
2~7	598 (8.24%)	422 (8.31%)	176 (8.08%)	
≥8	130 (1.79%)	92 (1.81%)	38 (1.75%)	
Unknown	1922 (26.5%)	1359 (26.8%)	563 (25.9%)	
Distant metastasis**				0.967
No	4696 (64.7%)	3283 (64.6%)	1413 (64.9%)	
Yes	485 (6.68%)	339 (6.67%)	146 (6.71%)	
Unknown	2075 (28.6%)	1457 (28.7%)	618 (28.4%)	
Peritoneal cytology				0.115
Negative	2532 (34.9%)	1778 (35.0%)	754 (34.6%)	
Positive	528 (7.28%)	377 (7.42%)	151 (6.94%)	
Suspicious	87 (1.20%)	51 (1.00%)	36 (1.65%)	
Unknown	4109 (56.6%)	2873 (56.6%)	1236 (56.8%)	
Operation of lymph node				0.643
Lymphadenectomy	4871 (67.1%)	3397 (66.9%)	1474 (67.7%)	
None	1782 (24.6%)	1262 (24.8%)	520 (23.9%)	

Sentinel lymph node biopsy	218 (3.00%)	157 (3.09%)	61 (2.80%)	
Biopsy/Unknown	385 (5.31%)	263 (5.18%)	122 (5.60%)	
Radiotherapy				0.288
Yes	2761 (38.1%)	1912 (37.6%)	849 (39.0%)	
No/Unknown	4495 (61.9%)	3167 (62.4%)	1328 (61.0%)	
Chemotherapy				0.270
Yes	2775 (38.2%)	1921 (37.8%)	854 (39.2%)	
No/Unknown	4481 (61.8%)	3158 (62.2%)	1323 (60.8%)	
Neoadjuvant treatment				0.306
Yes	203 (2.80%)	68 (3.12%)	135 (2.66%)	
No/Unknown	7053 (97.2%)	2109 (96.9%)	4944 (97.3%)	

\*SEER-Stage was derived from summary stage 2000 (1998-2017) variable and combined summary stage (2004+). \*\*Distant metastasis was derived from Mets at DX-bone, DX-brain, DX-liver, and DX-lung, Mets at DX-Distant LN, and Mets at DX-Other variables. OS: Overall survival; CSS: Cancer-specific survival; SEER: Surveillance, Epidemiology, and End Results; AJCC: American Joint Committee on Cancer; NPR-Lymph node: Number of positive regional lymph node.

**Table S2.** Univariate Cox regression analysis in the training set of mixed endometrial carcinoma for overall survival and cancer-specific survival

Characteristics	Univariate analysis of OS		Univariate analysis of CSS	
	Hazard Ratio (95% CI)	<i>P</i>	Hazard Ratio (95% CI)	<i>P</i>
<b>Age at diagnosis (y)</b>				
≤63	Reference		Reference	
64~77	2.38 [2.12-2.68]	<0.001	1.94 [1.69-2.23]	<0.001
≥78	5.60 [4.86-6.46]	<0.001	3.32 [2.77-3.97]	<0.001
<b>Race</b>				
White	Reference		Reference	
Black	1.70 [1.46-1.97]	<0.001	2.14 [1.81-2.52]	<0.001
Asian/Pacific Islander	0.78 [0.63-0.97]	0.022	0.91 [0.72-1.17]	0.477
American Indian/ Alaska Native	0.54 [0.20-1.44]	0.218	0.20 [0.03-1.43]	0.109
Unknown	0.67 [0.25-1.79]	0.425	0.96 [0.36-2.55]	0.927
<b>Marital status</b>				
Married	Reference		Reference	
Unmarried	1.17 [1.01-1.35]	0.031	1.12 [0.94-1.32]	0.202
Divorced/Separated	1.33 [1.13-1.56]	<0.001	1.32 [1.09-1.61]	0.004
Widowed	2.31 [2.03-2.64]	<0.001	1.89 [1.60-2.23]	<0.001
Unknown	1.12 [0.84-1.48]	0.455	1.09 [0.78-1.52]	0.630
<b>Tumor size (mm)</b>				

1~38	Reference		Reference	
39~59	1.36 [1.14-1.62]	<0.001	1.65 [1.32-2.05]	<0.001
≥60	2.46 [2.09-2.90]	<0.001	3.29 [2.70-4.01]	<0.001
Unknown	1.18 [1.03-1.35]	0.018	1.35 [1.13-1.61]	<0.001
Grade				
Grade I	Reference		Reference	
Grade II	2.89 [2.25-3.70]	<0.001	4.86 [3.19-7.39]	<0.001
Grade III	6.30 [5.01-7.92]	<0.001	14.0 [9.41-20.8]	<0.001
Grade IV	6.99 [5.46-8.96]	<0.001	15.6 [10.4-23.4]	<0.001
Unknown	3.21 [2.50-4.11]	<0.001	6.49 [4.31-9.79]	<0.001
SEER-Stage				
Localized	Reference		Reference	
Regional	2.85 [2.54-3.21]	<0.001	4.84 [4.13-5.67]	<0.001
Distant	9.32 [8.09-10.7]	<0.001	18.0 [15.1-21.5]	<0.001
Unknown	2.91 [1.56-5.45]	<0.001	3.73 [1.66-8.40]	0.002
AJCC-Stage				
I	Reference		Reference	
II	2.12 [1.69-2.65]	<0.001	3.09 [2.32-4.12]	<0.001
III	3.26 [2.83-3.76]	<0.001	5.61 [4.65-6.75]	<0.001
IV	10.0 [8.51-11.8]	<0.001	18.8 [15.4-22.9]	<0.001
Unknown	1.61 [1.39-1.85]	<0.001	2.34 [1.93-2.84]	<0.001
AJCC-T				

T1	Reference		Reference	
T2	2.13 [1.78-2.55]	<0.001	2.86 [2.29-3.59]	<0.001
T3	4.20 [3.67-4.81]	<0.001	6.62 [5.62-7.80]	<0.001
T4	9.81 [7.55-12.7]	<0.001	15.5 [11.8-20.6]	<0.001
Unknown	1.39 [1.21-1.59]	<0.001	1.75 [1.47-2.08]	<0.001
NPR-Lymph node				
0	Reference		Reference	
1	2.45 [2.00-2.99]	<0.001	3.30 [2.62-4.15]	<0.001
2~7	3.09 [2.65-3.61]	<0.001	4.27 [3.59-5.09]	<0.001
≥8	4.75 [3.65-6.20]	<0.001	6.53 [4.90-8.70]	<0.001
Unknown	1.55 [1.38-1.76]	<0.001	1.68 [1.44-1.96]	<0.001
Distant metastasis				
No	Reference		Reference	
Yes	6.88 [5.94-7.96]	<0.001	8.82 [7.53-10.3]	<0.001
Unknown	1.27 [1.13-1.44]	<0.001	1.18 [1.01-1.37]	0.0316
Peritoneal cytology				
Negative	Reference		Reference	
Positive	3.38 [2.81-4.05]	<0.001	3.84 [3.13-4.71]	<0.001
Suspicious	1.23 [0.64-2.39]	0.536	1.32 [0.62-2.80]	0.468
Unknown	1.44 [1.27-1.64]	<0.001	1.47 [1.26-1.71]	<0.001
Operation of lymph node				
Lymphadenectomy	Reference		Reference	



None	1.17 [1.04-1.31]	0.011	1.10 [0.96-1.27]	0.178
Sentinel lymph node biopsy	0.47 [0.25-0.87]	0.016	0.45 [0.22-0.90]	0.024
Biopsy/Unknown	1.03 [0.85-1.26]	0.746	0.98 [0.75-1.27]	0.863
<b>Radiotherapy</b>				
Yes	Reference		Reference	
No/Unknown	0.98 [0.89-1.09]	0.769	0.94 [0.83-1.07]	0.324
<b>Chemotherapy</b>				
Yes	Reference		Reference	
No/Unknown	0.47 [0.42-0.52]	<0.001	0.31 [0.27-0.35]	<0.001
<b>Neoadjuvant treatment</b>				
Yes	Reference		Reference	
No/Unknown	0.53 [0.40-0.70]	<0.001	0.43 [0.32-0.58]	<0.001

OS: Overall survival; CSS: Cancer-specific survival; SEER: Surveillance, Epidemiology, and End Results; AJCC: American Joint Committee on Cancer; NPR-Lymph node: Number of positive regional lymph node; CI: Confidence interval.

**Table S3.** Univariate Cox regression analysis in the test set of mixed endometrial carcinoma for overall survival and cancer-specific survival

Characteristics	Univariate analysis of OS		Univariate analysis of CSS	
	Hazard Ratio (95% CI)	<i>P</i>	Hazard Ratio (95% CI)	<i>P</i>
<b>Age at diagnosis (y)</b>				
≤63	Reference		Reference	
64~77	1.98 [1.66-2.38]	<0.001	1.79 [1.44-2.21]	<0.001
≥78	4.70 [3.79-5.82]	<0.001	2.74 [2.05-3.65]	<0.001
<b>Race</b>				
White	Reference		Reference	
Black	1.59 [1.27-2.01]	<0.001	1.74 [1.32-2.29]	<0.001
Asian/Pacific Islander	1.09 [0.82-1.45]	0.537	1.34 [0.97-1.86]	0.079
American Indian/ Alaska Native	1.16 [0.44-3.12]	0.761	1.96 [0.73-5.26]	0.181
Unknown	0.47 [0.07-3.34]	0.450	0.69 [0.10-4.89]	0.707
<b>Marital status</b>				
Married	Reference		Reference	
Unmarried	1.35 [1.08-1.68]	0.007	1.19 [0.91-1.56]	0.194
Divorced/Separated	1.24 [0.95-1.63]	0.112	1.03 [0.73-1.44]	0.875
Widowed	2.53 [2.07-3.09]	<0.001	2.00 [1.55-2.57]	<0.001
Unknown	1.12 [0.72-1.74]	0.628	0.67 [0.34-1.31]	0.239
<b>Tumor size (mm)</b>				

1~38	Reference		Reference	
39~59	1.48 [1.13-1.95]	0.005	1.67 [1.17-2.38]	0.005
≥60	2.57 [2.01-3.30]	<0.001	3.96 [2.93-5.36]	<0.001
Unknown	1.24 [1.00-1.54]	0.046	1.36 [1.02-1.80]	0.034
<b>Grade</b>				
Grade I	Reference		Reference	
Grade II	1.47 [1.06-2.05]	0.023	2.17 [1.31-3.61]	0.003
Grade III	4.27 [3.22-5.68]	<0.001	7.64 [4.90-11.9]	<0.001
Grade IV	4.67 [3.42-6.38]	<0.001	8.26 [5.18-13.2]	<0.001
Unknown	2.00 [1.44-2.77]	<0.001	3.08 [1.90-5.01]	<0.001
<b>SEER-Stage</b>				
Localized	Reference		Reference	
Regional	2.54 [2.13-3.04]	<0.001	3.92 [3.07-5.00]	<0.001
Distant	8.35 [6.70-10.4]	<0.001	16.4 [12.5-21.4]	<0.001
Unknown	0.76 [0.19-3.06]	0.700	0.95 [0.13-6.83]	0.962
<b>AJCC-Stage</b>				
I	Reference		Reference	
II	2.26 [1.62-3.14]	<0.001	2.38 [1.47-3.85]	<0.001
III	2.68 [2.15-3.35]	<0.001	4.80 [3.61-6.39]	<0.001
IV	9.10 [7.06-11.7]	<0.001	17.5 [12.9-23.8]	<0.001
Unknown	1.57 [1.26-1.96]	<0.001	2.14 [1.59-2.88]	<0.001
<b>AJCC-T</b>				

T1	Reference		Reference	
T2	2.33 [1.78-3.04]	<0.001	2.61 [1.84-3.72]	<0.001
T3	3.65 [2.96-4.51]	<0.001	5.80 [4.50-7.47]	<0.001
T4	6.92 [4.42-10.8]	<0.001	11.6 [7.24-18.7]	<0.001
Unknown	1.36 [1.10-1.68]	0.005	1.55 [1.18-2.04]	0.002
NPR-Lymph node				
0	Reference		Reference	
1	2.13 [1.54-2.94]	<0.001	3.13 [2.19-4.48]	<0.001
2~7	2.73 [2.13-3.50]	<0.001	3.65 [2.73-4.87]	<0.001
≥8	4.53 [3.03-6.78]	<0.001	5.75 [3.61-9.16]	<0.001
Unknown	1.84 [1.53-2.21]	<0.001	1.96 [1.55-2.49]	<0.001
Distant metastasis				
No	Reference		Reference	
Yes	6.60 [5.22-8.34]	<0.001	9.65 [7.46-12.5]	<0.001
Unknown	1.40 [1.16-1.68]	<0.001	1.52 [1.21-1.92]	<0.001
Peritoneal cytology				
Negative	Reference		Reference	
Positive	2.90 [2.15-3.92]	<0.001	4.38 [3.13-6.12]	<0.001
Suspicious	0.53 [0.17-1.65]	0.272	0.58 [0.14-2.35]	0.443
Unknown	1.46 [1.20-1.78]	<0.001	1.70 [1.32-2.17]	<0.001
Operation of lymph node				
Lymphadenectomy	Reference		Reference	

None	1.40 [1.16-1.67]	<0.001	1.24 [0.99-1.56]	0.059
Sentinel lymph node biopsy	0.29 [0.07-1.16]	0.080	0.35 [0.09-1.42]	0.144
Biopsy/Unknown	1.11 [0.83-1.49]	0.472	1.14 [0.78-1.66]	0.499
Radiotherapy				
Yes	Reference		Reference	
No/Unknown	1.26 [1.07-1.49]	0.006	1.20 [0.98-1.48]	0.078
Chemotherapy				
Yes	Reference		Reference	
No/Unknown	0.57 [0.49-0.67]	<0.001	0.35 [0.29-0.43]	<0.001
Neoadjuvant treatment				
Yes	Reference		Reference	
No/Unknown	0.37 [0.26-0.51]	<0.001	0.33 [0.22-0.48]	<0.001

OS: Overall survival; CSS: Cancer-specific survival; SEER: Surveillance, Epidemiology, and End Results; AJCC: American Joint Committee on Cancer; NPR-Lymph node: Number of positive regional lymph node; CI: Confidence interval.

**Table S4.** Clinical characteristics of the validation set of mixed endometrial carcinomas

Characteristics	The validation set
	No. (%)
Age at diagnosis (y)	
≤63	2966 (53.0%)
64~77	2073 (37.1%)
≥78	553 (9.89%)
Race	
White	4415 (79.0%)
Black	702 (12.6%)
Asian/Pacific Islander	418 (7.47%)
American Indian/Alaska Native	27 (0.48%)
Unknown	30 (0.54%)
Marital status	
Married	2752 (49.2%)
Unmarried	1122 (20.1%)
Divorced/Separated	641 (11.5%)
Widowed	832 (14.9%)
Unknown	245 (4.38%)
Tumor size (mm)	
1~38	1339 (23.9%)
39~59	739 (13.2%)

---


≥60	676 (12.1%)
Unknown	2838 (50.8%)
Grade	
Grade I	993 (17.8%)
Grade II	1091 (19.5%)
Grade III	1469 (26.3%)
Grade IV	726 (13.0%)
Unknown	1313 (23.5%)
SEER-Stage	
Localized	3352 (59.9%)
Regional	1752 (31.3%)
Distant	457 (8.17%)
Unknown	31 (0.55%)
AJCC-T	
T1	2689 (48.1%)
T2	425 (7.60%)
T3	658 (11.8%)
T4	80 (1.43%)
Unknown	1740 (31.1%)
NPR-Lymph node	
0	3300 (59.0%)
1	284 (5.08%)

---

2~7	486 (8.69%)
≥8	97 (1.73%)
Unknown	1425 (25.5%)
Operation of lymph node	
Lymphadenectomy	3853 (68.9%)
None	1306 (23.4%)
Sentinel lymph node biopsy	114 (2.04%)
Biopsy/Unknown	319 (5.70%)
Radiotherapy	
Yes	2140 (38.3%)
No/Unknown	3452 (61.7%)
Chemotherapy	
Yes	2131 (38.1%)
No/Unknown	3461 (61.9%)
Neoadjuvant treatment	
Yes	150 (2.68%)
No/Unknown	5442 (97.32%)

OS: Overall survival; CSS: Cancer-specific survival; SEER: Surveillance, Epidemiology, and End Results; AJCC: American Joint Committee on Cancer; NPR-Lymph node: Number of positive regional lymph node.







**Figure S1.** Calculation of the optimal cut-off values of continuous variables. The optimal cut-off of age at diagnosis (y) (A-C), tumor size (mm) (D-F), and NPR-Lymph node (G-I) were calculated by the X-tile software based on overall survival using the data of the training and test sets. The dark dots in the X-tile plots were the sites according to the highest  $\chi^2$  value defined by Kaplan-Meier survival analysis and Log-Rank test in age at diagnosis (y) (A), tumor size (mm) (D), and NPR-Lymph node (G). Histograms (B: age at diagnosis (y), 63 and 77; E: tumor size (mm), 38 and 59; H: NPR-Lymph node, 1 and 7) in good-, median-, and poor-prognosis groups according to the optimal cut-off value. In Kaplan-Meier survival analysis, cyan bars represented

the good-prognosis groups, grey bars represented the median-prognosis groups, and purple bars represent the poor-prognosis groups. Kaplan-Meier survival analysis of overall survival by optimal cutoff values (C: age at diagnosis (y); F: tumor size (mm) I: NPR-Lymph node). NPR-Lymph node: Number of positive regional lymph node.


A










**Figure S2.** Screening of the independent prognostic factors by multivariate Cox regression analysis in the test set. (A) Overall survival (OS). (B) Cancer-specific survival (CSS). SEER:


Surveillance, Epidemiology, and End Results; AJCC: American Joint Committee on Cancer;  
 NPR-Lymph node: Number of positive regional lymph node.






**Figure S3.** Validation of the nomogram in the test set. The performance of the established nomogram was compared to grade, SEER-Stage, AJCC-T, NPR-Lymph node, and tumor size using the time-dependent AUC, ROC, and DCA. ROC curves for OS (A) and CSS (B) in mixed endometrial carcinoma patients at 1-, 3-, 5- and 10-year. DCA curves for OS (C) and CSS (D). The x-axis shows the threshold probability, and the y-axis measures the net benefit. Time-dependent AUC for OS (E) and CSS (F). Calibration curves for the established nomogram for predicting 1-, 3-, 5- and 10-year OS (G) and CSS (H). \**P*: Other models vs nomogram model; OS: Overall survival; CSS: Cancer-specific survival; SEER: Surveillance, Epidemiology, and End Results; AJCC: American Joint Committee on Cancer; NPR-Lymph node: Number of positive regional lymph node; AUC: Area under the curve; CI: Confidence interval.






**Figure S4.** Validation of the nomogram in the validation set. The performance of the established nomogram was compared to grade, SEER-Stage, AJCC-T, NPR-Lymph node, and tumor size using the time-dependent AUC, ROC, and DCA. ROC curves for OS (A) and CSS (B) in mixed endometrial carcinoma patients at 1-, 3-, 5- and 10-year. DCA curves for OS (C) and CSS (D). The x-axis shows the threshold probability, and the y-axis measures the net benefit. Time-dependent AUC for OS (E) and CSS (F). Calibration curves for the established nomogram for predicting 1-, 3-, 5- and 10-year OS (G) and CSS (H). \**P*: Other models vs nomogram model; OS: Overall survival; CSS: Cancer-specific survival; SEER: Surveillance, Epidemiology, and End Results; AJCC: American Joint Committee on Cancer; NPR-Lymph node: Number of positive regional lymph node; AUC: Area under the curve; CI: Confidence interval.





**Figure S5.** Kaplan-Meier survival curves of mixed endometrial carcinoma patients for cancer-specific survival by the risk score (low-risk, intermediate-risk, and high-risk) with chemotherapy, radiotherapy, neoadjuvant treatment, and operation of lymph node in the total patients (training, test, and validation set). Operation of lymph node with sentinel lymph node biopsy and biopsy/unknown were excluded due to small sample size. (A) Low-risk mixed endometrial carcinoma patients. (B) Intermediate-risk mixed endometrial carcinoma patients. (C) High-risk mixed endometrial carcinoma patients.



**Figure S6.** Kaplan-Meier survival curves of mixed endometrial carcinoma patients for cancer-specific survival by the NPR-Lymph node with chemotherapy, radiotherapy, and neoadjuvant treatment in the total patients (training, test, and validation set). (A) Mixed endometrial carcinoma patients with NPR-Lymph node of 0. (B) Mixed endometrial carcinoma patients with NPR-Lymph node of 1. (C) Mixed endometrial carcinoma patients with NPR-Lymph node of 2 to 7. (D) Mixed endometrial carcinoma patients with NPR-Lymph node of  $\geq 8$ . NPR-Lymphnode: Number of positive regional lymph node.